PET-Adapted Treatment of Hodgkin Lymphoma

Patients with bulky stage I–II disease were safely spared radiation therapy if they were PET-negative following two cycles of induction chemotherapy.

Combined-modality treatment — chemotherapy plus radiotherapy — has been a standard of care for patients with limited-stage bulky Hodgkin lymphoma. Investigators now report a single-arm, multicenter, phase 2 trial in which patients with stage I–II bulky disease received two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) followed by interim restaging positron emission tomography scan (PET2). Patients with negative scans (Deauville score 1–3) then received four additional ABVD cycles, while patients with positive scans (Deauville score 4–5) received four cycles of escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by 30 Gy involved-field radiation t…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

PET-Adapted Treatment of Hodgkin Lymphoma

Topics

Reviewing Author